

Attorney's Docket No. 238/086

Applicant or Patentee: Nigel Beeley and Kathryn Prickett  
Serial or Patent No.: To Be Assigned  
Filed or Issued: Filed herewith  
For: NOVEL EXENDIN AGONIST COMPOUNDS

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27(c)) – SMALL BUSINESS CONCERN**

I hereby declare that I am

the owner of the small business concern identified below:  
 an official of the small business concern empowered to act on behalf of the concern identified below:

Name of Concern: Amylin Pharmaceuticals, Inc.  
Address of Concern: 9373 Towne Centre Drive  
San Diego, CA 92121

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-part or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled

**NOVEL EXENDIN AGONIST COMPOUNDS**

by inventor(s) Nigel Beeley and Kathryn Prickett

described in

the specification filed herewith  
 the application serial no. \_\_\_\_\_, filed \_\_\_\_\_.  
 patent no. \_\_\_\_\_, issued \_\_\_\_\_.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

Attorney's Docket No. 238/086

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

 Individual       Small Business Concern       Nonprofit Organization

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

 Individual       Small Business Concern       Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING \_\_\_\_\_ Nancy K. Dahl

TITLE OF PERSON SIGNING \_\_\_\_\_ Vice President and General Counsel

ADDRESS OF PERSON SIGNING \_\_\_\_\_ Amylin Pharmaceuticals, Inc.,

9373 Towne Centre Drive

San Diego, CA 92121

SIGNATURE \_\_\_\_\_

DATE \_\_\_\_\_ 5-4-00